These injections were sufficient to attenuate weight gain (Fig. 4g), improve glucose tolerance, and improve hepatic steatosis (Fig. 4h, i), demonstrating the potential for FSH treatment to improve the symptoms of metabolic syndrome. The gene discussed is BRD2; the disease is fatty liver disease.